The overall objective of the proposed research is to investigate the molecular and cellular mechanisms of two genetically related, but functionally different, lysosomal glycosidases, alpha-galactosidase A (alpha-Gal A) and alpha-N-acetylgalactosaminidase (alpha-Gal B) by characterization of their respective structural domains, enzyme complexes, and deficiency diseases. To facilitate these studies, we 1) isolated and characterized the full-length human and murine cDNAs and the complete human genomic sequences encoding alpha-Gal A and alpha-Gal B, 2) developed methods for their high-level eukaryotic expression and purification, 3) identified a variety of mutations that result in their respective lysosomal disorders, Fabry and Schindler diseases. We propose to determine the structures of these two remarkably homologous glycosidases whose genes presumably evolved by duplication and diverged to have different substrate specificities, stabilities and N-linked oligosaccharide chains. Large amounts of recombinant alpha-Gal A and alpha-Gal B will be produced and purified for crystallization and solution of their 3D structures, and for the biochemical and computer-assisted analyses of their respective structural domains, including N-glycosylation sites and the oligosaccharide structures of each, galactose recognition and catalytic residues in active site domains, cysteines in disulfide bridges, and subunit association domains. To investigate the metabolic and cellular pathologies of these inborn errors of glycolipid and glycoprotein metabolism, alpha-Gal A or alpha-Gal B deficient mice will be generated using murine genomic constructs altered for homologous recombination in ES cells followed by blastocyst implantation. Characterization of the biochemical, morphologic and pathophysiologic alterations in the animal models may provide insights into the pathogenesis of their respective human lysosomal disease. Finally, the role of alpha-Gal B in neuroaxonal transport will be explored by determining the alpha-Gal B distribution in neural tissues, characterizing the effect of alpha-Gal B inhibition on axonal transport in sciatic nerve preparations, and studies of alternative alpha-Gal B substrate specificities (e.g., alpha-N-acetylgalactosaminylphosphate-linked residues involved in neural-specific cell-cell adhesion. These studies should provide fundamental understanding of the molecular and cellular mechanisms of these two related glycosidases in health and disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37DK034045-12
Application #
2139221
Study Section
Medical Biochemistry Study Section (MEDB)
Project Start
1984-05-01
Project End
1997-04-30
Budget Start
1995-06-01
Budget End
1996-04-30
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Cantatore-Francis, Julie L; Cohen-Pfeffer, Jessica; Balwani, Manisha et al. (2010) Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation. Arch Dermatol 146:529-33
Khanna, Richie; Soska, Rebecca; Lun, Yi et al. (2010) The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther 18:23-33
Schiffmann, Raphael; Warnock, David G; Banikazemi, Maryam et al. (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102-11
Hwu, Wuh-Liang; Chien, Yin-Hsiu; Lee, Ni-Chung et al. (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30:1397-405
Banikazemi, Maryam; Bultas, Jan; Waldek, Stephen et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77-86
Grace, Marie E; Balwani, Manisha; Nazarenko, Irina et al. (2007) Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring. Hum Mutat 28:866-73
Laradi, S; Tukel, T; Khediri, S et al. (2006) Mucopolysaccharidosis type IV: N-acetylgalactosamine-6-sulfatase mutations in Tunisian patients. Mol Genet Metab 87:213-8
Nance, Christopher S; Klein, Christopher J; Banikazemi, Maryam et al. (2006) Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol 63:453-7
Desnick, Robert J; Banikazemi, Maryam (2006) Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. Nephrol Ther 2 Suppl 2:S172-85
Spada, Marco; Pagliardini, Severo; Yasuda, Makiko et al. (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31-40

Showing the most recent 10 out of 73 publications